5TSP
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase (NanI) in complex with a CHES
5TSP の概要
| エントリーDOI | 10.2210/pdb5tsp/pdb |
| 分子名称 | Sialidase, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, CALCIUM ION, ... (4 entities in total) |
| 機能のキーワード | neuraminidase, hydrolase |
| 由来する生物種 | Clostridium perfringens ATCC 13124 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 103715.10 |
| 構造登録者 | Lee, Y.,Youn, H.-S.,Lee, J.-G.,An, J.Y.,Park, K.R.,Kang, J.Y.,Jin, M.S.,Ryu, Y.B.,Park, K.H.,Eom, S.H. (登録日: 2016-10-31, 公開日: 2017-03-29, 最終更新日: 2023-11-08) |
| 主引用文献 | Lee, Y.,Youn, H.-S.,Lee, J.-G.,An, J.Y.,Park, K.R.,Kang, J.Y.,Ryu, Y.B.,Jin, M.S.,Park, K.H.,Eom, S.H. Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid Biochem. Biophys. Res. Commun., 486:470-475, 2017 Cited by PubMed Abstract: Anti-bacterial and anti-viral neuraminidase agents inhibit neuraminidase activity catalyzing the hydrolysis of terminal N-acetylneuraminic acid (Neu5Ac) from glycoconjugates and help to prevent the host pathogenesis that lead to fatal infectious diseases including influenza, bacteremia, sepsis, and cholera. Emerging antibiotic and drug resistances to commonly used anti-neuraminidase agents such as oseltamivir (Tamiflu) and zanamivir (Relenza) have highlighted the need to develop new anti-neuraminidase drugs. We obtained a serendipitous complex crystal of the catalytic domain of Clostridium perfringens neuraminidase (CpNanI) with 2-(cyclohexylamino)ethanesulfonic acid (CHES) as a buffer. Here, we report the crystal structure of CpNanI in complex with CHES at 1.24 Å resolution. Amphipathic CHES binds to the catalytic site of CpNanI similar to the substrate (Neu5Ac) binding site. The 2-aminoethanesulfonic acid moiety and cyclohexyl groups of CHES interact with the cluster of three arginine residues and with the hydrophobic pocket of the CpNanI catalytic site. In addition, a structural comparison with other bacterial and human neuraminidases suggests that CHES could serve as a scaffold for the development of new anti-neuraminidase agents targeting CpNanI. PubMed: 28315686DOI: 10.1016/j.bbrc.2017.03.064 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.24 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






